The Emergence of Biosimilars

At Juno, our goal is twofold: increase patient access to high quality, lifesaving medicines and increase value within the Australian healthcare system.

Biosimilars and interchangeable biologic products present an opportunity to patients, healthcare professionals and the government, by providing increased patient access to therapies, whilst helping maintain the long-term viability and financial sustainability of the Australian and New Zealand healthcare systems.

We believe that we have the right expertise and strategies to effectively partner with biologic developers whose brands are reaching their patent expiry, plus biosimilar developers with plans to launch in Australia and New Zealand.

 

Estimated Global Savings To Healthcare Systems

References:
1.Medicines for Europe: Biosimilar Medicines clinical use Available at: http://bit.ly/2j0EJGt. Accessed March 2018. 2.The benefits of biosimilar medicines. Available at: https://bit.ly/2DsdBvR. Accessed April 2018. 3.United Nations. World Aging Report. Available at: http://bit.ly/1Y2LeF4. Accessed March 2018. 4.Healthy Aging at a Glance 2011. Available at: http://bit.ly/2ptzYJS. Accessed March 2018. 5.QuintilesIMS Institute for Healthcare Informatics. Global Medicines Use in 2020: Outlook and Implications. 2015. Available at: http://bit.ly/1H9Nze3. Accessed March 2018. 6.QuintilesIMS Institute for Healthcare Informatics. Delivering on the Potential of Biosimilar Medicines. Report. 2016. Available at: http://bit.ly/2D2HuPe. Accessed March 2018. 7.Orlewska L, et al. Med Sci Monit. 2011;17:SR1-13. 8.Li E, et al. Drug Des Devel Ther 2015;9:3247–55. 9.What you need to know about biosimilar medicinal products. Available at: http://bit.ly/29AZtNM. Accessed March 2018. 10.Biosimilar Medicines Group. Biosimilar Medicines Group handbook 2016. Available at: http://bit.ly/2q3qx0w. Accessed March 2018. 11.Simon-Kucher & Partners. Payers’ price & market access policies supporting a sustainable biosimilar medicines market. Available at: http://bit.ly/2q3qx0w Accessed March 2018. 12.Cornes P, Muenzberg M. Pharma Horizon 2016;1:35–38.